Just as asthma impacts people differently, existing treatment options serve some patients better than others. Some people’s asthma conditions are mild or moderate, and intermittent symptoms may be well controlled by the current standard of care.
Comments on ICER’s Draft Evidence Report on Tezepelumab for Severe Asthma
